Published January 1, 2022
| Version v1
Publication
Additional file 6 of S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer
Creators
-
Hongnan Mo1, 2
-
Xuefeng Li3, 4, 5, 6, 7, 8, 9
-
Xue Yu7, 1, 2
-
Hongyan Chen1, 2, 10
-
Shichao Guo1, 2
- Zhangfu Li1, 2
-
Shuang Wang11, 12, 13, 14, 15, 16, 17, 18, 19, 7, 20, 21, 22, 23, 24
-
Caiming Li24
- Jiashu Han2, 1
-
Ming Fu1, 2, 25
-
Yongmei Song1, 2
-
Dan Li26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 1, 2, 37, 38, 39, 40, 41, 42, 43, 24, 17, 44
-
Fei Ma2, 45, 1
- 1. Peking Union Medical College Hospital
- 2. Chinese Academy of Medical Sciences & Peking Union Medical College
- 3. The Ohio State University
- 4. Southern University of Science and Technology
- 5. Georgetown University Medical Center
- 6. Georgetown University
- 7. Dalian Medical University
- 8. Northeast Forestry University
- 9. Sheng Jing Hospital
- 10. Xuzhou Medical College
- 11. Yangzhou University
- 12. Chongqing University
- 13. University of Rhode Island
- 14. Huazhong Agricultural University
- 15. University of Chinese Academy of Sciences
- 16. Peking University First Hospital
- 17. Peking University
- 18. Nanjing University
- 19. Inner Mongolia University
- 20. Liaoning Cancer Hospital & Institute
- 21. Beijing University of Chemical Technology
- 22. Henan Academy of Agricultural Sciences
- 23. China University of Petroleum, Beijing
- 24. Chinese Academy of Sciences
- 25. Harbin Institute of Technology
- 26. Huazhong University of Science and Technology
- 27. United States Food and Drug Administration
- 28. Beijing Academy of Agricultural and Forestry Sciences
- 29. Hainan Medical University
- 30. Hubei University of Medicine
- 31. First Affiliated Hospital of Xi'an Jiaotong University
- 32. Sun Yat-sen University
- 33. Fifth Affiliated Hospital of Sun Yat-sen University
- 34. First Affiliated Hospital of Liaoning Medical University
- 35. Liaoning Medical University
- 36. Lanzhou Veterinary Research Institute
- 37. The Sixth People's Hospital of Shenyang
- 38. National Institute for Communicable Disease Control and Prevention
- 39. Jilin Medical University
- 40. Jilin University
- 41. Fudan University
- 42. Central South University
- 43. Wuhan University
- 44. Chinese Center For Disease Control and Prevention
- 45. Lexington VA Health Care System
Description
Additional file 6: Supplementary Table S6. Clinical characteristics of patients received palbociclib treatment in the validation cohort.
Translated Descriptions
⚠️
This is an automatic machine translation with an accuracy of 90-95%
Translated Description (Arabic)
الملف الإضافي 6: الجدول التكميلي S6. الخصائص السريرية للمرضى الذين تلقوا علاج بالبوسيكليب في مجموعة التحقق من الصحة.Translated Description (French)
Dossier complémentaire 6 : Tableau complémentaire S6. Les caractéristiques cliniques des patients ont reçu un traitement par palbociclib dans la cohorte de validation.Translated Description (Spanish)
Expediente adicional 6: Cuadro Complementario S6. Características clínicas de los pacientes que recibieron tratamiento con palbociclib en la cohorte de validación.Additional details
Additional titles
- Translated title (Arabic)
- يمنح الملف الإضافي 6 من تضخيم S6K1 مقاومة فطرية لمثبطات CDK4/6 من خلال تنشيط مسار c - Myc في المرضى الذين يعانون من سرطان الثدي الإيجابي لمستقبلات هرمون الاستروجين
- Translated title (French)
- Le dossier supplémentaire 6 de l'amplification S6K1 confère une résistance innée aux inhibiteurs de CDK4/6 en activant la voie c-Myc chez les patientes atteintes d'un cancer du sein à récepteurs d'œstrogènes positifs
- Translated title (Spanish)
- El archivo adicional 6 de la amplificación de S6K1 confiere resistencia innata a los inhibidores de CDK4/6 a través de la activación de la vía c-Myc en pacientes con cáncer de mama positivo para receptores de estrógeno
Identifiers
- Other
- https://openalex.org/W4394263684
- DOI
- 10.6084/m9.figshare.20745216